Close up of clinical employee in clean room attire starting a cell manufacturing process on the CliniMACS Prodigy​

TCR-engineered T cells and CAR T cell manufacturing on clinical scale

Close up of clinical employee in clean room attire starting a cell manufacturing process on the CliniMACS Prodigy​

Engineered T cells for cancer therapy and other therapeutical applications

Chimeric antigen receptor (CAR) T cell therapy is undoubtedly leading a revolution in cancer therapy.1 Recent successes in treating hematologic malignancies with CAR T cell therapy and the availability of several commercial products have prompted increased interest in cancer immunotherapy.2 These advances have also opened new lines of research looking to optimize the safety and efficacy of CAR T cell therapies via complex gene engineering3 and promising developments like engineered T cell receptors (TCRs).4 More recently, genetically engineered T cells are also being applied in other indication areas like solid tumors, infectious diseases, and autoimmunity.5-7

Infographic on the CliniMACS Prodigy T Cell Transduction and CliniMACS Prodigy T Cell Transduction – Large-Scale used in CAR T cell and TCR-engineered T cell manufacturing
Overview of the CliniMACS Prodigy T Cell Transduction (TCT; above) and CliniMACS Prodigy T Cell Transduction – Large-Scale (TCT-LS; below) used in CAR T cell and TCR-engineered T cell manufacturing.

TCR-engineered T cells and CAR T cell manufacturing on the CliniMACS Prodigy®

Currently, CAR T cell and TCR T cell production consists of various complex process steps. GMP cell manufacturing is labor intensive, and as such, represents a significant challenge in further development of gene-modified T cell therapies. The CliniMACS Prodigy T Cell Transduction (TCT) and CliniMACS Prodigy T Cell Transduction – Large-Scale (TCT-LS) provide a unique all-in-one solution to this challenge. Well-established and widely used in clinical settings8–12, the CliniMACS Prodigy Platform generates gene-modified T cells via viral transduction in a standardized and automated process.13 The closed system is a breakthrough in cell manufacturing designed to facilitate the transition of novel strategies like TCR T cell therapies to clinical use.4

An overview of gene-engineered T cell manufacturing options with the CliniMACS Prodigy Platform

 CliniMACS Prodigy T Cell Transduction (TCT)CliniMACS Prodigy T Cell Transduction Large-Scale (TCT-LS)
Main applicationCAR T cell manufacturingTCR T cell manufacturing
General featuresT cell isolation, activation, viral transduction, expansion, rebuffering, and harvestT cell isolation, activation, viral transduction, expansion, rebuffering, and harvest
Starting materialHeterogenous blood products like whole blood, buffy coat, leukapheresisFresh or frozen leukapheresis
Gene engineering methodViral transduction (lentivirus or retrovirus)Viral transduction (lentivirus or retrovirus)
Culture capacity (volume)250 mL600 mL
Number of harvested T cells~5x109~2x1010

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notices click here.